Enlivex Advances Knee Osteoarthritis Treatment with Allocetra™

Enlivex's Promising Results in Knee Osteoarthritis Treatment with Allocetra™

Enlivex Therapeutics, a clinical-stage immunotherapy company, has announced positive safety results from the Phase I trial of their innovative treatment, Allocetra™, for knee osteoarthritis. The trial involved three sequential intra-articular knee injections, demonstrating a favorable safety profile in the first twelve patients. This success has led to the approval to proceed to the Phase II stage, which will be a double-blind, randomized, placebo-controlled study.

Understanding Knee Osteoarthritis

Knee osteoarthritis is a prevalent and debilitating condition affecting millions worldwide. In the United States alone, over 32.5 million individuals suffer from osteoarthritis, with projections indicating that 78 million Americans will be affected by 2040. The disease often develops in knees with prior ACL injuries, with 40% of men and 47% of women likely to develop the condition in their lifetime. The impact of osteoarthritis is significant, leading to over one million hospitalizations annually in the U.S., primarily for joint replacement surgeries. Despite its prevalence, there are currently no FDA or EMA-approved medications that can halt or reverse the structural damage caused by osteoarthritis.

About Enlivex Therapeutics

Enlivex is pioneering the development of Allocetra™, an off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state. This reprogramming is crucial for restoring immune balance and addressing life-threatening conditions. Allocetra™ offers hope for reducing pain and disability associated with osteoarthritis.

Forward-Looking Statements and Risks

Enlivex's forward-looking statements highlight the potential of Allocetra™ but also acknowledge inherent risks. These include the possibility of unsuccessful product development, failure to achieve expected results, and challenges posed by regulatory and competitive landscapes. Investors are advised to consider these risks as outlined in Enlivex's SEC filings.

Contact Information

For more information, contact Enlivex's CFO, Shachar Shlosberger, at shachar@enlivexpharm.com, or reach out to Dave Gentry, CEO of RedChip Companies, at ENLV@redchip.com.

For further details on Enlivex and Allocetra™, visit Enlivex's website.